Collegium Pharmaceutical Inc (COLL) Actualités

Form 144 - Report of proposed sale of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form S-8 - Securities to be offered to employees in employee benefit plans

Form 144 - Report of proposed sale of securities

Form 144 - Report of proposed sale of securities

Form 144 - Report of proposed sale of securities

Collegium to Participate in Upcoming Investor Conferences

STOUGHTON, Mass., March 04, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today...

Form 8-K - Current report

Collegium Reports Record Fourth Quarter and Full-Year 2024 Financial Results

– Generated Record Quarterly and Full-Year Net Revenue of $181.9 Million and $631.4 Million – – Reported...

Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors

Collegium to Report Fourth Quarter and Full-Year 2024 Financial Results on February 27, 2025

STOUGHTON, Mass., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today...

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities